Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00655031 · ClinicalTrials.gov registry record · Phase 2
Trial to Evaluate the Use of Pomegranate Concentrate (POMx) for the Prevention of Experimental Rhinovirus Infection
A Phase 2 study, sponsored by POM Wonderful.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00655031 is a Phase 2 study that has completed, run by POM Wonderful. The registered enrollment target is 150 participants.
The verdict
NCT00655031, a Phase 2 study, has completed, sponsored by POM Wonderful.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
Pomegranate has a long history of use in folk medicine. There is vast data on the health benefits of pomegranate fruit and juice. Multiple studies have established the strong antioxidative effects of pomegranate polyphenols (primarily the ellagitannin punicalagin) and their health effects. A vast number of animal and human clinical studies have provided evidence on effect of pomegranate products on reducing symptoms of common cold, reducing blood pressure, improving endothelial function, anti-tumor activity, and its anti-atherosclerotic activity. This study will evaluate the protective effect of a pomegranate concentrate (POMx) in decreasing the incidence and duration of the common cold among healthy adults.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Pomegranate Concentrate (POMx)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2008-04 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00655031
The ClinicalTrials.gov registry entry for NCT00655031 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is POM Wonderful, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00655031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00655031 about?
NCT00655031 is a clinical study titled "Trial to Evaluate the Use of Pomegranate Concentrate (POMx) for the Prevention of Experimental Rhinovirus Infection". Pomegranate has a long history of use in folk medicine. There is vast data on the health benefits of pomegranate fruit and juice. Multiple studies have established the strong antioxidative effects of pomegranate polyphenols (primarily the ellagitannin punicalagin) and their health effects. A vast nu...
What is the current status of trial NCT00655031?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2008-04. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00655031?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Pomegranate Concentrate (POMx) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00655031?
This trial is sponsored by POM Wonderful, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.